Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Clark Estates Inc. NY

Clark Estates Inc. NY lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 35,930 shares of the biopharmaceutical company’s stock after selling 4,345 shares during the quarter. Clark Estates Inc. NY’s holdings in Gilead Sciences were worth $3,319,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of GILD. Carrera Capital Advisors increased its holdings in Gilead Sciences by 30.7% in the 4th quarter. Carrera Capital Advisors now owns 33,400 shares of the biopharmaceutical company’s stock worth $3,085,000 after buying an additional 7,854 shares during the period. Victory Capital Management Inc. increased its stake in shares of Gilead Sciences by 19.1% in the fourth quarter. Victory Capital Management Inc. now owns 3,051,567 shares of the biopharmaceutical company’s stock worth $281,873,000 after acquiring an additional 489,955 shares during the period. Mainstream Capital Management LLC acquired a new position in Gilead Sciences during the fourth quarter valued at $55,000. Commerzbank Aktiengesellschaft FI boosted its holdings in Gilead Sciences by 4.6% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 10,463 shares of the biopharmaceutical company’s stock valued at $963,000 after purchasing an additional 464 shares during the last quarter. Finally, Synergy Investment Management LLC acquired a new stake in Gilead Sciences during the 4th quarter worth about $40,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 1.1 %

Shares of GILD opened at $114.74 on Wednesday. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $117.39. The firm has a market capitalization of $143.00 billion, a P/E ratio of 310.11, a P/E/G ratio of 0.71 and a beta of 0.21. The firm has a 50-day moving average price of $98.28 and a 200 day moving average price of $90.74. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.75%. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Analysts Set New Price Targets

A number of analysts have recently commented on GILD shares. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Citigroup started coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 price objective on the stock. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $105.00 to $120.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Piper Sandler raised their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Finally, Oppenheimer increased their target price on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research note on Tuesday. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $102.76.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 293,356 shares of company stock valued at $29,166,240. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.